Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Neoplasms 6Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Solid Tumor 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1

Interventions

Gemcitabine 20Cisplatin 17pembrolizumab 11Magnetic Resonance Spectroscopy 7durvalumab 5Platinum 5Irinotecan 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5Leucovorin 4Taxes 3Oxaliplatin 3Nivolumab 3Fluorodeoxyglucose F18 3Carboplatin 3Biopsy 3Bevacizumab 3spartalizumab 2pemigatinib 2ivosidenib 2fludarabine 2budigalimab 2atezolizumab 2Specimen Handling 2Radiosurgery 2Paclitaxel 2Immunoglobulin G 2Floxuridine 2FAPI-46 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cholangiocarcinoma × Ramucirumab × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡